주식/증권
📈 긍정적
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
요약
Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.